Advanced Parkinson’s disease treatment eligibility in France: an epidemiological study (EPIPARK)

Study identification

• EU PAS number:
  EUPAS20918
• Study ID:
  31124
• Official title and acronym:
  Advanced Parkinson’s disease treatment eligibility in France: an epidemiological study (EPIPARK)
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  This is an epidemiological, cross-sectional, descriptive, non-interventional, and multicenter study designed to estimate, in Metropolitan France, the size of the population of PD patients eligible for Duodopa®, in accordance with the conditions defined by the French Authority for Health in its Transparency Committee’s opinion. Two complementary parts will be done simultaneously: a CENSUS and a descriptive CORE part.
• Study status:
  Finalised

Research institutions and networks

Institutions

NA

Multiple centres: 38 centres are involved in the study

Study timelines

Date when funding contract was signed

Actual:18/06/2017

Study start date

Actual:26/07/2017

Data analysis start date

Planned:27/07/2018

Actual:20/09/2018

Date of final study report

Planned:05/07/2019

Actual:29/03/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AbbVie

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

H18-162